Key result
Percutaneous interatrial shunting safely improves PCWP, 6MWD, and NYHA class in HFpEF.
Why the study?
Effective management for HFpEF remains a major unmet clinical need due to limited evidence on medical treatment benefits, prompting the development of devices that reduce left atrial pressure.
Do percutaneous interatrial shunting devices improve hemodynamic and clinical parameters in patients with heart failure with preserved ejection fraction?
Do percutaneous interatrial shunting devices improve hemodynamic and clinical parameters in patients with heart failure with preserved ejection fraction?
Percutaneous interatrial shunting devices offer a promising strategy to improve hemodynamics and functional capacity in HFpEF, though data on hard clinical outcomes remain limited.
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of heart failure hospital admissions in the last years and is burdened by high mortality and poor quality of life. Providing effective management for HFpEF patients is a major unmet clinical need. Increase in left atrial pressure is the key determinant of pulmonary congestion, with consequent dyspnoea and exercise limitation. Evidence on benefits of medical treatment in HFpEF patients is limited. Thus, alternative strategies, including devices able to reduce left atrial pressure, through an interatrial communication determining a left-right shunt, were developed. This review aims to summarize evidence regarding the use of percutaneous interatrial shunting devices. These devices are safe and effective in improving hemodynamic and clinical parameters, including pulmonary capillary wedge pressure, 6-min walking distance, and New York Heart Association functional class. Data on cardiovascular mortality and re-hospitalization for heart failure are still scarce.
No takes yet. Share an insight, caveat, or question.
Riccardi et al. (2022) studied this question. Percutaneous interatrial shunting devices safely improve pulmonary capillary wedge pressure, 6-minute walking distance, and NYHA functional class in patients with HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: